Browse News

Found 280 articles

• Krystal Biotech to Present at Upcoming June 2023 Investor Conferences

  6/5/2023

  Krystal Biotech, Inc. a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced that the Company will participate in the following upcoming investor conferences.

• Mirati To Encore Compelling Clinical Data Demonstrating Adagrasib's Potential as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors at 2023 ASCO Annual Meeting

  5/30/2023

  Mirati Therapeutics, Inc.®  (NASDAQ: MRTX), a commercial stage biotechnology company, today announced presentations and posters to be shared at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating the utility of adagrasib across multiple tumor types.

• FDA Approves Groundbreaking New Product Utilizing Berkshire Sterile Excipient Gel to Treat 'Butterfly Children'

  5/25/2023

  On May 19, 2023, Krystal Biotech, a client of Berkshire Sterile Manufacturing (BSM), received FDA approval for VYJUVEK™, the first-ever topical gene therapy approved to treat dystrophic epidermolysis bullosa (DEB) in children and adults six months of age or older.

• Orsini Specialty Pharmacy Selected as part of the Limited Specialty Pharmacy Network For VYJUVEK™, the First Gene Therapy for the Treatment of Dystrophic Epidermolysis Bullosa

  5/23/2023

  Orsini Specialty Pharmacy announced that Krystal Biotech has selected it as part of the limited specialty pharmacy network for VYJUVEK™, a topical gene therapy for the treatment of Dystrophic Epidermolysis Bullosa.

• 

  Krystal Gets First FDA Approval for Redosable Gene Therapy, Rare Skin Disease

  5/22/2023

  The topical treatment Vyjuvek got the FDA’s greenlight, making it the first redosable gene therapy and the first therapeutic for the rare skin disease dystrophic epidermolysis bullosa.

• Krystal Biotech Announces $160 Million Private Placement Equity Financing

  5/22/2023

  Krystal Biotech, Inc. today announced that it has entered into a securities purchase agreement for the sale of 1,729,729 shares of its common stock at $92.50 per share in a private placement (the PIPE) to certain qualified institutional buyers.

•  Landmark victory for individuals living with DEB and their families, the FDA announced their approval of Krystal Biotech’s VYJUVEK™ for the treatment of Dystrophic Epidermolysis Bullosa (DEB).

  5/19/2023

  400 million people around the world are affected by a rare disease. 95% of rare diseases lack an FDA approved treatment or cure.

• Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa

  5/19/2023

  Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announced the US Food and Drug Administration (FDA) has approved VYJUVEK™ (beremagene geperpavec-svdt) for the treatment of patients six months of age or older with dystrophic epidermolysis bullosa (DEB).

• FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa

  5/19/2023

  Today, the U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.  

• 

  FDA Action Alert: Krystal, Genmab/AbbVie, Pfizer and Intercept

  5/15/2023

  The FDA has four events lined up this week, including a target action date for Krystal Biotech's gene therapy for a rare skin disease and an adcomm meeting for Pfizer’s RSV vaccine candidate.

• Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates

  5/9/2023

  Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the first quarter 2023 along with recent pipeline and corporate updates.

• Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights

  5/8/2023

  Krystal Biotech, Inc. today reported financial results and key operational progress updates for the first quarter ended March 31, 2023.

• Journal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors

  4/26/2023

  Mirati Therapeutics, Inc.® (NASDAQ: MRTX) announced today the Journal of Clinical Oncology published in a Rapid Communication data indicating adagrasib, a potent and selective KRASG12C inhibitor, is well tolerated and demonstrates meaningful clinical activity in patients with pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), and other solid tumors harboring a KRASG12C mutation.

• Krystal Biotech Announces Clinical Data on Topical Application of B-VEC to the Eye to Treat Ocular Complications in a Patient with Dystrophic Epidermolysis Bullosa Under a Compassionate Use Program

  4/24/2023

  Krystal Biotech, Inc. announced today that the Company presented new data on the compassionate use of topical beremagene geperpavec (B-VEC) to treat a patient with dystrophic epidermolysis bullosa (DEB) with recurrent cicatrizing conjunctivitis at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting on April 23, 2023.

• Krystal Biotech to Present at Association for Research in Vision and Ophthalmology Annual Meeting

  4/13/2023

  Krystal Biotech, Inc. announced today that the Company will be presenting new data on the compassionate use of topical beremagene geperpavec (B-VEC) to treat a patient with dystrophic epidermolysis bullosa (DEB) with recurrent cicatrizing conjunctivitis at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting being held from April 23-27, 2023 in New Orleans, LA.

• Idorsia Files Petition with the Drug Enforcement Administration (DEA) Urging Them to De-Schedule Dual Orexin Receptor Antagonist Class of Insomnia Medications

  4/4/2023

  Yesterday, a Citizen Petition (CP) was filed on behalf of Idorsia Pharmaceuticals (SIX: IDIA), urging the Drug Enforcement Administration (DEA) to de-schedule the dual orexin receptor antagonist (DORA) class of chronic insomnia medications based on a review of evidence from available data, including post-marketing surveillance data.

• Krystal Biotech Appoints Catherine Mazzacco to Board of Directors

  3/6/2023

  Krystal Biotech, Inc. today announced the appointment of Catherine Mazzacco to its Board of Directors.

• Krystal Biotech to Present at the 43rd Annual TD Cowen Health Care Conference

  3/2/2023

  Krystal Biotech, Inc. announced today that the Company will participate in the 43rd Annual TD Cowen Health Care Conference, which is taking place in Boston from March 6-8.

• Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates

  2/28/2023

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the fourth quarter and full year of 2022 along with recent corporate updates.

• Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress

  2/27/2023

  Krystal Biotech, Inc. today reported financial results and key operational updates for the fourth quarter and year ending December 31, 2022.